Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer

Background The large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED)({"type":"clinical-trial","attrs":{"text":"NCT01306890","term_id":"NCT01306890"}}NCT01306890), evaluated sipuleucel‐T immunotherapy for asymptomatic/minimally symptomatic metastatic castration‐resistant prostate cancer (mCRPC).